“Translational Regenerative Medicine market set to grow to $118bn by 2025” says new Visiongain report

03 February 2020
Pharma

Visiongain has launched a new pharma report Translational Regenerative Medicine Market Forecast 2020-2030: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.

Ramla Salad, the lead analyst of the report commented "The translational regenerative medicine market is expected to grow significantly due to the advances in technology and improvements in regulatory frameworks. The expected number of gene therapies is anticipated to increase due to the introduction of the Regenerative Medicine Advanced therapy designation (RMAT) because it provides incentives for the development of advanced therapies. In addition, many governments in various regions of the globe have shown an interest in promoting the development of translational regenerative medicine. The strong governmental support has eased the process of product commercialisation and market access which will result in an influx of products reaching the translational regenerative medicine market in the coming decade."

Leading companies featured in the report include Astellas Pharma, Athersys, AxoGen, Inc., Organogenesis Holdings, Inc., Osiris Therapeutics, Inc., uniQure N.V., Vericell Corporation and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Precision Medicine Market Report 2022-2032

The global precision medicine market was valued at US$63,333 million in 2021 and is projected to grow at a CAGR of 10.8% during the forecast period 2022-2032.

05 July 2022

Read

Visiongain Publishes Biologics Market Report 2022-2032

The global biologics market was valued at US$382.85 billion in 2022 and is projected to grow at a CAGR of 8.82% during the forecast period 2022-2032.

04 July 2022

Read

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

Read

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever